Home | Welcome to Contract Pharma   
Last Updated Saturday, May 25 2013
Print RSS Feed

Breaking News

Related Searches: Industry News •
PharmaNet Opens Brazil Office

February 18, 2009
PharmaNet Development Group opened a new office in Sao Paulo, Brazil. The new office is part of the company's efforts to provide services in this region, which is considered to be a desired location for clinical research due to its qualified investigators  Read More »
BASi

February 18, 2009
Anthony S. Chilton, Ph.D. has been named chief operating officer, scientific services, at BASi.   Read More »
WuXi PharmaTech

February 17, 2009
WuXi PharmaTech's chief financial officer, Benson Tsang is leaving the company at the end of February. Edward Hu, chief operating officer, will serve as acting chief financial officer until a replacement is found.  Read More »
Financial Report: Hospira 4Q

February 17, 2009
In the Americas Pharmaceutical Specialty Injectables sales were $347.2 million in the quarter (-1%) and $1.3 billion for the year (+7%). Other Pharma revenue was $147.6 million in the quarter (-5%) and $522 million for the year (-5%).  Read More »
PAREXEL Consulting

February 17, 2009
Anders Neil, Ph.D. has been appointed principal consultant at PAREXEL's European Product Development Practice.   Read More »
WIL Research Acquires Midwest BioResearch

February 13, 2009
WIL Research Laboratories has acquired Midwest BioResearch (MBR). The two companies will integrate their service offerings and share best practices and marketing.   Read More »
Novartis Licenses Blood Thinner

February 13, 2009
Portola Pharmaceuticals has entered into an exclusive worldwide license agreement with Novartis. Novartis will develop and commercialize Portola's intravenous (i.v.) and oral P2Y12 ADP receptor antagonist, elinogrel, currently in Phase II as a potential a  Read More »
Norwich Pharmaceuticals

February 13, 2009
Norwich Pharmaceuticals, Inc. is expanding its development services offerings through a selective buildup of technical personnel and capital investments in specialized equipment.  Read More »
Merck To Acquire Biogeneric Portfolio

February 12, 2009
Merck has entered into an agreement with Insmed, Inc. to purchase its portfolio of follow-on biologic therapeutic candidates and its commercial manufacturing facilities in Boulder, CO for $130 million in cash.  Read More »
OctoPlus, Galapagos Sign Manufacturing Contract

February 12, 2009
OctoPlus N.V. has signed a pharmaceutical development contract with Galapagos N.V.   Read More »
Financial Report: Cambrex Corp. 4Q

February 12, 2009
Sales in the quarter were up 1% excluding the impact of foreign exchange. Sales of controlled substances increased due to higher demand, offset by decreases due to delays in certain custom development projects, lower sales of generic APIs, and lower contr  Read More »
Financial Report: Genzyme 4Q

February 11, 2009
Fabrazyme sales were $126 million in the quarter (+10%) and $494 million for the year (+17%). Sales of Cerezyme were $305 million in the quarter (+2%) and for the year were $1.2 billion (+9%).  Read More »
Financial Report: Sanofi-Aventis 4Q

February 11, 2009
Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%).  Read More »
Sanofi-Aventis

February 11, 2009
Jean-Pierre Lehner, M.D., has been appointed senior vice president, chief medical officer, Sanofi-Aventis. Dr. Lehner reports to Marc Cluzel, senior vice president, R&D.   Read More »
Financial Report: Elan

February 10, 2009
Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition.  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: